Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression.

Sim WJ, Iyengar PV, Lama D, Lui SKL, Ng HC, Haviv-Shapira L, Domany E, Kappei D, Tan TZ, Saie A, Jaynes PW, Verma CS, Kumar AP, Rouanne M, Ha HK, Radulescu C, Ten Dijke P, Eichhorn PJA, Thiery JP.

Nat Commun. 2019 Sep 25;10(1):4349. doi: 10.1038/s41467-019-12241-2.

2.

MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma.

Li B, Yan J, Phyu T, Fan S, Chung TH, Mustafa NB, Lin B, Wang L, Eichhorn PJA, Goh BC, Ng SB, Kappei D, Chng WJ.

Blood. 2019 Aug 21. pii: blood.2019000381. doi: 10.1182/blood.2019000381. [Epub ahead of print]

PMID:
31434700
3.

Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma.

Saei A, Eichhorn PJA.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1176. doi: 10.3390/cancers11081176. Review.

4.

Structural and Functional Characterization of Ubiquitin Variant Inhibitors of USP15.

Teyra J, Singer AU, Schmitges FW, Jaynes P, Kit Leng Lui S, Polyak MJ, Fodil N, Krieger JR, Tong J, Schwerdtfeger C, Brasher BB, Ceccarelli DFJ, Moffat J, Sicheri F, Moran MF, Gros P, Eichhorn PJA, Lenter M, Boehmelt G, Sidhu SS.

Structure. 2019 Apr 2;27(4):590-605.e5. doi: 10.1016/j.str.2019.01.002. Epub 2019 Jan 31.

PMID:
30713027
5.

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma.

Saei A, Eichhorn PJA.

Mol Cell Oncol. 2018 Sep 5;5(5):e1497862. doi: 10.1080/23723556.2018.1497862. eCollection 2018.

6.

Platforms for Investigating LncRNA Functions.

Charles Richard JL, Eichhorn PJA.

SLAS Technol. 2018 Dec;23(6):493-506. doi: 10.1177/2472630318780639. Epub 2018 Jun 26. Review.

7.

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

Saei A, Palafox M, Benoukraf T, Kumari N, Jaynes PW, Iyengar PV, Muñoz-Couselo E, Nuciforo P, Cortés J, Nötzel C, Kumarakulasinghe NB, Richard JLC, Bin Adam Isa ZF, Pang B, Guzman M, Siqin Z, Yang H, Tam WL, Serra V, Eichhorn PJA.

J Exp Med. 2018 Jul 2;215(7):1913-1928. doi: 10.1084/jem.20171960. Epub 2018 Jun 7.

8.

Deciphering the roles of lncRNAs in breast development and disease.

Richard JLC, Eichhorn PJA.

Oncotarget. 2018 Feb 28;9(28):20179-20212. doi: 10.18632/oncotarget.24591. eCollection 2018 Apr 13. Review.

9.

The roles of ubiquitin modifying enzymes in neoplastic disease.

Kumari N, Jaynes PW, Saei A, Iyengar PV, Richard JLC, Eichhorn PJA.

Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):456-483. doi: 10.1016/j.bbcan.2017.09.002. Epub 2017 Sep 18. Review.

PMID:
28923280
10.

Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma.

Kong LR, Tan TZ, Ong WR, Bi C, Huynh H, Lee SC, Chng WJ, Eichhorn PJA, Goh BC.

Mol Oncol. 2017 Aug;11(8):965-980. doi: 10.1002/1878-0261.12064. Epub 2017 May 30.

11.

USP26 regulates TGF-β signaling by deubiquitinating and stabilizing SMAD7.

Kit Leng Lui S, Iyengar PV, Jaynes P, Isa ZFBA, Pang B, Tan TZ, Eichhorn PJA.

EMBO Rep. 2017 May;18(5):797-808. doi: 10.15252/embr.201643270. Epub 2017 Apr 5.

12.

Deubiquitylating enzyme USP9x regulates hippo pathway activity by controlling angiomotin protein turnover.

Thanh Nguyen H, Andrejeva D, Gupta R, Choudhary C, Hong X, Eichhorn PJ, Loya AC, Cohen SM.

Cell Discov. 2016 Mar 29;2:16001. doi: 10.1038/celldisc.2016.1. eCollection 2016.

13.

USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination.

Iyengar PV, Jaynes P, Rodon L, Lama D, Law KP, Lim YP, Verma C, Seoane J, Eichhorn PJ.

Sci Rep. 2015 Oct 5;5:14733. doi: 10.1038/srep14733.

14.

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

Serra V, Eichhorn PJ, García-García C, Ibrahim YH, Prudkin L, Sánchez G, Rodríguez O, Antón P, Parra JL, Marlow S, Scaltriti M, Pérez-Garcia J, Prat A, Arribas J, Hahn WC, Kim SY, Baselga J.

J Clin Invest. 2013 Jun;123(6):2551-63. doi: 10.1172/JCI66343. Epub 2013 May 1. Erratum in: J Clin Invest. 2014 Mar 3;124(3):1418.

15.

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma.

Eichhorn PJ, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A, Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J.

Nat Med. 2012 Feb 19;18(3):429-35. doi: 10.1038/nm.2619.

PMID:
22344298
16.

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.

Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3761-6. doi: 10.1073/pnas.1014835108. Epub 2011 Feb 14.

17.

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.

Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J.

Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. Epub 2011 Jan 31.

18.

HER2 signatures in breast cancer: ready to go to print?

Eichhorn PJ, Baselga J.

J Clin Oncol. 2010 Apr 10;28(11):1809-10. doi: 10.1200/JCO.2009.26.7146. Epub 2010 Mar 15. No abstract available.

PMID:
20231675
19.

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J.

Cancer Res. 2008 Nov 15;68(22):9221-30. doi: 10.1158/0008-5472.CAN-08-1740.

20.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.

Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.

21.

Protein phosphatase 2A regulatory subunits and cancer.

Eichhorn PJ, Creyghton MP, Bernards R.

Biochim Biophys Acta. 2009 Jan;1795(1):1-15. doi: 10.1016/j.bbcan.2008.05.005. Epub 2008 Jun 3. Review.

PMID:
18588945
22.

A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC.

Eichhorn PJ, Creyghton MP, Wilhelmsen K, van Dam H, Bernards R.

PLoS Genet. 2007 Dec;3(12):e218.

23.

PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle.

Creyghton MP, Roël G, Eichhorn PJ, Vredeveld LC, Destrée O, Bernards R.

Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5397-402. Epub 2006 Mar 27.

24.

PR72, a novel regulator of Wnt signaling required for Naked cuticle function.

Creyghton MP, Roël G, Eichhorn PJ, Hijmans EM, Maurer I, Destrée O, Bernards R.

Genes Dev. 2005 Feb 1;19(3):376-86.

25.

Concurrent development of eruptive xanthogranulomas and hematologic malignancy: two case reports.

Larson MJ, Bandel C, Eichhorn PJ, Cruz PD Jr.

J Am Acad Dermatol. 2004 Jun;50(6):976-8. Review. No abstract available.

PMID:
15153909
26.

Traumatic pseudoaneurysm of the superficial temporal artery: two cases and review of the literature.

Evans CC, Larson MJ, Eichhorn PJ, Taylor RS.

J Am Acad Dermatol. 2003 Nov;49(5 Suppl):S286-8. Review.

PMID:
14576656
27.

Nontuberculous mycobacterial infections of the skin.

Weitzul S, Eichhorn PJ, Pandya AG.

Dermatol Clin. 2000 Apr;18(2):359-77, xi-xii. Review.

PMID:
10791163

Supplemental Content

Loading ...
Support Center